ライフサイエンスコーパス: duration of therapy

1 ne or both drugs for >or=80% of the expected duration of therapy).

2 istered for 1 month, 2 months, or the entire duration of therapy.

3 ve immune responses that otherwise limit the duration of therapy.

4 leave questions unanswered regarding optimal duration of therapy.

5 aintained an undetectable viral load for the duration of therapy.

6 , various estrogen preparations or doses, or duration of therapy.

7 ct of CPAP is evident only after an extended duration of therapy.

8 ism is sensitive using a sufficient dose and duration of therapy.

9 sist and become the dominant variant for the duration of therapy.

10 ir inherent immunogenicity, which limits the duration of therapy.

11 operative site bleeding was not affected by duration of therapy.

12 CV RNA at week 4 and qualified for the short duration of therapy.

13 efit tuberculosis patients by shortening the duration of therapy.

14 ce of cure and the opportunity for a shorter duration of therapy.

15 ic hypothermia is dependent on the onset and duration of therapy.

16 Infection risk is also likely to vary with duration of therapy.

17 ffectively prevented acute rejection for the duration of therapy.

18 of level 1 evidence to guide the choice and duration of therapy.

19 c or vasopressor support and correlated with duration of therapy.

20 failure of this treatment increases with the duration of therapy.

21 th regards to antifungal agent employed, and duration of therapy.

22 etectable in the majority of animals for the duration of therapy.

23 response rates and the potential for shorter durations of therapy.

24 144/231 [62%]; p=0.0095), and a shorter mean duration of therapy (12.5 days [SD 10.7] vs 17.7 [28.1];

25 After the switch to tocilizumab (median duration of therapy, 18 months), the median annualized r

26 ribavirin doses for >or=80% of the expected duration of therapy and (2) patients who received reduce

27 e of episodes of acute intoxication and that duration of therapy and cumulative dose are the major de

28 Explicit instructions about expected duration of therapy and discussions about medication adv

29 nterferon + ribavirin because of the shorter duration of therapy and high rates of SVR (89%-90%).

30 e with morphine is associated with a lengthy duration of therapy and hospitalization.

31 SU after eOIT is enhanced with longer duration of therapy and increases the likelihood of tole

32 s suggest a higher response rate with longer duration of therapy and non-type 1 genotypes.

33 romising, many unanswered questions, such as duration of therapy and optimal end points to evaluate e

34 type is an important criteria in determining duration of therapy and predictor of sustained virologic

35 Secondary outcomes included the duration of therapy and rates of subsequent infections.

36 There was no significant association between duration of therapy and resistance for any antibiotic cl

37 ave helped guide decisions earlier regarding duration of therapy and resuscitation status.

38 The short duration of therapy and small volume irradiated allowed

39 The optimal duration of therapy and the balance of risks and benefit

40 Evaluation of effects based on duration of therapy and time off IFN prior to transplant

41 ting drugs are being assessed to shorten the duration of therapy and to treat multidrug-resistant tub

42 The median durations of therapy and follow-up were 29 and 36 months

43 atty acids as a treatment, (b) determine the duration of therapy, and (c) test whether there is benef

44 advantages of induction dosing, the optimal duration of therapy, and further understanding of the fr

45 calcium supplementation, type of vitamin D, duration of therapy, and sex, but reduced sample sizes m

46 atifloxacin) regimens have failed to shorten duration of therapy, and the new tuberculosis drug pipel

47 ine demographics, PHT medication(s), dosage, duration of therapy, and time to referral.

48 B, factors associated with treatment of ASB, durations of therapy, and frequency of complications inc

49 was given in lieu of or after DI, with total duration of therapy approximately 3 years for boys and 2

50 paration, dose, route of administration, and duration of therapy are dictated by the stage of disease

51 and trials that evaluate optimal timing and duration of therapy are in progress as part of induction

52 serum vancomycin concentrations and greater duration of therapy are independently associated with in

53 s and antagonists in heart failure vary with duration of therapy, as do the effects of beta-AR agonis

54 e that combination of IFN and ribavirin with duration of therapy based on the viral genotype, is a co

55 n alfa plus cytarabine (65.6%) and the short duration of therapy before crossover in these patients (

56 Duration of therapy before study enrollment was correlat

57 ore, race, overall antibiotic utilization or duration of therapy between the 2 yrs of study.

58 The duration of therapy beyond which continued use is futile

59 It occurred more commonly with greater duration of therapy, but improved following dose reducti

60 for extracorporeal treatment is provided and duration of therapy can be guided through the careful mo

61 Drug dose, patient age, and duration of therapy did not account for the variability.

62 Duration of therapy did not significantly differ between

63 Longer durations of therapy did not appear to increase the risk

64 atherogenesis and have implications for the duration of therapies directed at leukocyte recruitment.

65 s; method and equipment used for evacuation; duration of therapy; evidence of complications; results

66 benefit of novel agent-based CT versus fixed duration of therapy (FDT) in patients with newly diagnos

67 ne the relationship between HBIg failure and duration of therapy, five additional treatment failures

68 Questions remain about optimal duration of therapy following deployment of drug-eluting

69 the initiation of anti-TNFalpha therapy, the duration of therapy following the onset of inactive dise

70 ons are needed; efforts to assess and reduce duration of therapy for CAP should be strongly considere

71 The duration of therapy for CAP was excessive at our institu

72 The appropriate duration of therapy for catheter-associated Staphylococc

73 The optimal duration of therapy for chronic osteomyelitis remains un

74 assess the optimal therapeutic approach and duration of therapy for cryptococcosis in transplant rec

75 Type, dose, and duration of therapy for each patient were at the physici

76 Early detection and adequate duration of therapy for ESBL-producing Enterobacteriacea

77 LDL-C-lowering therapy; 2) the intensity and duration of therapy for inducing atherosclerosis regress

78 a 3-month course seemed to be an appropriate duration of therapy for most patients.

79 Optimal duration of therapy for patients with HCV genotype 6 is

80 8 h in the electronic medical record and the duration of therapy for pneumonia and culture-negative s

81 atasvir-containing regimens could reduce the duration of therapy for these patients.

82 high rates of treatment of ASB and prolonged durations of therapy for ASB and symptomatic UTIs.

83 t of asymptomatic bacteriuria (ASB) and long durations of therapy for symptomatic urinary tract infec

84 By shortening the duration of therapy from the currently recommended 12 we

85 the effects of novel therapeutic agents and duration of therapy, have become available.

86 for significant confounders (age, ethnicity, duration of therapy, hepatitis C virus status, and HOMA-

87 itment for early rapid diagnosis, shortening duration of therapy, improving treatment outcomes, and p

88 latent infection and possibly shortening the duration of therapy in active TB.

89 Several trials to reduce the duration of therapy in MDR and drug-susceptible tubercul

90 ddressed the issues of choice of therapy and duration of therapy in selected bacteremic disease, such

91 ly explored as biomarkers to personalize the duration of therapy in TB.

92 ribavirin can be used to define the optimal duration of therapy in the setting of HEV infection.

93 sine [5-FC] for a median of 2 weeks); median duration of therapy including azole eradication therapy

94 Additionally, specific drug delivery issues, duration of therapy, initiation of treatment and managem

95 e of disease, specific drug delivery issues, duration of therapy, management of bony metastases with

96 d on culture results, and using the shortest duration of therapy needed for documented infections.

97 Long duration of therapy needed for HIV-infected children req

98 d pyrazinamide may substantially shorten the duration of therapy needed to cure human tuberculosis an

99 s the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

100 ard of care, but the optimal combination and duration of therapy needs to be determined.

101 ed infection, possibly related to inadequate duration of therapy, occurred among 32% who ultimately a

102 comycin (odds ratio = 1.112; p < 0.001), and duration of therapy (odds ratio = 1.041; p </= 0.001) we

103 We enrolled 34,701 patients with mean duration of therapy of 18 months.

104 significant, consistent effect on the median duration of therapy of laBCC and mBCC.

105 effects, depending on the cell type and the duration of therapy, one of which includes the ability t

106 justing for drug exposure and accounting for duration of therapy, only neutropenia was independently

107 proved by suppressing acid and extending the duration of therapy (optimization).

108 R, 1.79; 95% CI, 1.15-2.78), and appropriate duration of therapy (OR, 2.13; 95% CI, 1.24-3.64).

109 tics could have the potential to shorten the duration of therapy, prevent resistance development and

110 t after clinical response and an appropriate duration of therapy, probably at least 12 months, appear

111 30.4 weeks, which indicates that the 48-week duration of therapy provided a suboptimal probability of

112 The duration of therapy ranged from 2 to 72 hours.

113 The duration of therapy ranged from 23 to 188 hrs in group 1

114 as well as the appropriate starting dose and duration of therapy remain controversial.

115 proved response rates, although the adequate duration of therapy remains unclear.

116 es are necessary to assess the efficacy, the duration of therapy required for effective results, and

117 The duration of therapy required to completely eliminate the

118 Longer duration of therapy showed statistically significant inc

119 : -0.30; 95% CI: -4.19, 3.59; p = 0.878) and duration of therapy (slope: 0.18; 95% CI: -0.22, 0.59; p

120 udy offers the first estimate of the average duration of therapy that is required to eliminate stem-l

121 se, including the particular azole used, the duration of therapy, the reason therapy was discontinued

122 The mean duration of therapy was 10.8 days for liposomal amphoter

123 The median duration of therapy was 12 weeks (range, 2 to 111).

124 The mean duration of therapy was 12.9 mo (range, 3 to 24 mo).

125 sus 800 mg (758.2-800.0) placebo, and median duration of therapy was 120.0 days (IQR 43.0-266.0) for

126 Median duration of therapy was 16 months (range: 5 to 35 months

127 The median duration of therapy was 2.79, 0.4, and 1.63 years, respe

128 The median duration of therapy was 20 days (range, 8-77 days); 26 p

129 The mean duration of therapy was 27 months.

130 Median duration of therapy was 35.8 weeks (95% CI, 35.1-36.5 we

131 The median duration of therapy was 57 months (interquartile range,

132 Mean (SD) duration of therapy was 6.0 (3.3) months (range, 1-18.4

133 As a 2 x 2 factorial design, duration of therapy was also addressed and was previousl

134 The median anticipated duration of therapy was comparable at 28 (interquartile

135 The duration of therapy was determined by baseline patient c

136 The duration of therapy was meant to be limited to four cycl

137 However, the duration of therapy was short, and whether therapy of lo

138 The mean dose of losartan and the mean duration of therapy were 14.2+/-5.3 mg. kg(-1). d(-1) an

139 he effects of vitamin D because the dose and duration of therapy were insufficient to raise 25(OH)D c

140 The mortality and duration of therapy were similar for patients treated wi

141 mptoms prior to therapy, treatment type, and duration of therapy) were recorded.

142 the estimated parameters was correlated with duration of therapy when actual CPAP use was not taken i

143 ntibodies will achieve greater intensity and duration of therapy, while allowing repeat administratio

144 The duration of therapy with AmB (14 vs 11 days, p=0.05) and

145 Little is known about the optimal duration of therapy with an anti-tumor necrosis factor (

146 dence intervals for categories of cumulative duration of therapy with any of the three agents combine

147 ing antibiotics to PCT levels may reduce the duration of therapy without increasing treatment failure

148 ctivity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereb